But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
A win in Apollo-B should open up the multi-billion cardiomyopathy market, but questions remain.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.